450,000 SLXN shares issued to Moringa Sponsor, LP in note conversion

Rhea-AI Filing Summary

Silexion Therapeutics Corp insider entities led by Ilan Levin and Moringa Sponsor, LP reported several share and warrant changes. On August 7, 2025, Moringa Sponsor, LP made a pro rata distribution of 5,550 ordinary shares and 935 warrants to its limited partners for no consideration, leaving 6,970 ordinary shares and 372 warrants indirectly held through that entity. On September 15, 2025, Moringa Sponsor, LP received 450,000 ordinary shares upon conversion of $1,800,000 of principal under a convertible promissory note at $4.00 per share, an issuance approved by the board.

The reporting persons state they dispute the validity of this 450,000-share issuance and do not concede beneficial ownership of those shares. The filing also notes 1-for-9 and 1-for-15 reverse share splits that reduced reported share and warrant counts, and includes 1,482 ordinary shares held via Greenstar, L.P. for informational purposes.

Insights

Equity ownership & governance analyst

Large insider-related share issuance via note conversion with disputed validity.

The filing shows Moringa Sponsor, LP, a 10% owner of Silexion Therapeutics Corp, converting $1,800,000 of a convertible promissory note into 450,000 ordinary shares at $4.00 per share on September 15, 2025, with board approval. This materially increases the number of shares attributed to Moringa Sponsor, LP, alongside earlier pro rata distributions of 5,550 ordinary shares and 935 warrants on August 7, 2025 for no consideration.

Ilan Levin controls Moringa Partners Ltd., the general partner of both Moringa Sponsor, LP and Greenstar, L.P., giving him sole voting and investment authority over these securities while he disclaims beneficial ownership beyond his indirect pecuniary interest. The reporting persons expressly state they dispute the validity of the 450,000-share issuance and do not concede beneficial ownership of those shares, so the practical impact depends on how that dispute is resolved. Reverse splits of 1-for-9 and 1-for-15 have already reduced the reported counts of ordinary shares and warrants.

Subsequent company disclosures may clarify the treatment of the disputed 450,000 shares and any further changes in holdings by Moringa Sponsor, LP or Greenstar, L.P. as Ilan Levin remains both a director and a 10% owner for reporting purposes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levin Ilan

(Last) (First) (Middle)

C/O SILEXION THERAPEUTICS CORP

12 ABBA HILLEL ROAD

(Street)

RAMAT GAN L3 5250608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/07/2025		J(1)		5,550(2)	D	$0	6,970(2)	I	By Moringa Sponsor, LP.(3)
Ordinary Shares	09/15/2025		A(4)		450,000(4)	A	$4	456,970(2)	I	By Moringa Sponsor, LP.(3)
Ordinary Shares(5)								1,482(2)	I	By Greenstar, L.P.(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy)	$1,552.5(7)	08/07/2025		J(1)			935(7)	09/14/2024	08/15/2029	Ordinary Shares	935(7)	$0	372(7)	I	By Moringa Sponsor, LP.(3)

1. Name and Address of Reporting Person^*

Levin Ilan

(Last) (First) (Middle)

C/O SILEXION THERAPEUTICS CORP

12 ABBA HILLEL ROAD

(Street)

RAMAT GAN L3 5250608

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Moringa Sponsor, LP

(Last) (First) (Middle)

C/O MORINGA ACQUISITION CORP

250 PARK AVENUE, 7TH FLOOR

(Street)

NEW YORK NY 11040

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP.

2. The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.

3. Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein.

4. The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares.

5. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

6. Moringa Partners Ltd. serves as the sole general partner of Greenstar, L.P. As a result of Ilan Levin being the sole equity owner and serving as the sole director of Moringa Partners Ltd. (as described in footnote (3) above), Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares. The limited partnership interests of Greenstar, L.P. may be held from time to time by various individuals and entities. Mr. Levin disclaims beneficial ownership of the subject ordinary shares except to the extent of his indirect pecuniary interest therein.

7. The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025.

	/s/ Ilan Levin	01/27/2026
	Moringa Sponsor, LP, by Moringa Partners Ltd., its sole general partner, by: /s/ Ilan Levin, director	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did SLXN report for Moringa Sponsor, LP on this Form 4?

The filing reports a pro rata distribution on August 7, 2025 of 5,550 ordinary shares and 935 warrants by Moringa Sponsor, LP to its limited partners for no consideration, and an issuance on September 15, 2025 of 450,000 ordinary shares to Moringa Sponsor, LP upon conversion of $1,800,000 of note principal at $4.00 per share.

Who controls the SLXN shares held by Moringa Sponsor, LP and Greenstar, L.P.?

Ilan Levin is the sole equity owner and sole director of Moringa Partners Ltd., which is the sole general partner of both Moringa Sponsor, LP and Greenstar, L.P.. He therefore has sole voting and investment authority over the reported ordinary shares and warrants, while disclaiming beneficial ownership except for his indirect pecuniary interest.

What is the nature of the 450,000 SLXN shares issued in the note conversion?

On September 15, 2025, 450,000 ordinary shares were issued to Moringa Sponsor, LP upon conversion of $1,800,000 of principal under a convertible promissory note dated August 15, 2024, at a conversion price of $4.00 per share, with the issuance approved by the issuer's board of directors.

Why do the reporting persons dispute the 450,000 share issuance in the SLXN Form 4?

In footnote (4), the reporting persons state they "expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares," indicating they are reporting the transaction while contesting whether the issuance itself is valid and whether they should be deemed beneficial owners.

How did reverse share splits affect the SLXN share and warrant amounts reported?

Footnotes explain that the numbers of ordinary shares and warrants reflect a 1-for-9 reverse share split effective November 29, 2024 and a 1-for-15 reverse share split effective July 29, 2025, which reduced the counts and increased warrant exercise prices proportionately.

What SLXN holdings are reported for Greenstar, L.P. in this Form 4?

The filing lists 1,482 ordinary shares held indirectly through Greenstar, L.P., with no transactions in those securities during the period; the holdings are included for informational purposes only.

Is Ilan Levin personally buying or selling SLXN shares in this Form 4?

The transactions are reported as indirect holdings through entities. Shares and warrants are held by Moringa Sponsor, LP and Greenstar, L.P., where Ilan Levin controls voting and investment authority via Moringa Partners Ltd., and he disclaims beneficial ownership except for his indirect pecuniary interest.